These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12728440)

  • 1. The evolving role of pelvic radiation therapy.
    Roberts T; Roach M
    Semin Radiat Oncol; 2003 Apr; 13(2):109-20. PubMed ID: 12728440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.
    Mantini G; Tagliaferri L; Mattiucci GC; Balducci M; Frascino V; Dinapoli N; Di Gesù C; Ippolito E; Morganti AG; Cellini N
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e721-6. PubMed ID: 21277100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic lymph node irradiation for prostate cancer: who, why, and when?
    Wang D; Lawton C
    Semin Radiat Oncol; 2008 Jan; 18(1):35-40. PubMed ID: 18082586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
    Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
    J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Vargas CE; Demanes J; Boike TP; Barnaba MC; Skoolisariyaporn P; Schour L; Gustafson GS; Gonzalez J; Martinez AA
    Am J Clin Oncol; 2006 Oct; 29(5):451-7. PubMed ID: 17023778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
    Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):695-701. PubMed ID: 15708247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of high risk prostate cancer.
    Akduman B; Crawford ED
    J Urol; 2003 Jun; 169(6):1993-8. PubMed ID: 12771704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
    Lawton CA; DeSilvio M; Roach M; Uhl V; Kirsch R; Seider M; Rotman M; Jones C; Asbell S; Valicenti R; Hahn S; Thomas CR
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):646-55. PubMed ID: 17531401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
    Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.